ProVerum Limited Welcomes Tyler Binney to Its Board of Directors
On April 25, 2025, ProVerum Ltd., a leading innovator in the medical technology field, proudly announced the appointment of Tyler Binney to its Board of Directors. ProVerum is known for developing the ProVee® System—a transformative, minimally invasive solution for managing benign prostatic hyperplasia (BPH). Binney's appointment comes at a crucial time for the company as it gears up for significant growth and commercialization.
With an impressive background in the medical device industry, Tyler Binney has previously held notable positions, which include President and CEO of Relievant Medsystems, Inc. His tenure there ended with a successful acquisition by Boston Scientific in November 2023, a deal that underscored Tyler's capability in driving commercial success, considering it was valued at $850 million along with performance-based earnouts. Furthermore, his earlier experience encompasses leadership roles at Teleflex and NeoTract, where he excelled in promoting innovative urology technologies.
In expressing his enthusiasm for joining ProVerum, Binney stated, "I am thrilled to join the ProVerum Board at such an exciting time in the company's growth. The ProVee® System truly has the potential to transform the way BPH is managed and treated. I look forward to contributing to that success and supporting ProVerum's executive management as they prepare for commercialization." This sentiment highlights not only his optimism but also the transformative potential of the ProVee® System within the healthcare landscape.
Paul Bateman, CEO of ProVerum, welcomed Binney's addition to the team, stating, "Tyler brings a wealth of experience in launching disruptive technologies and developing high-growth companies. His knowledge of the BPH market will be invaluable as we work to launch our novel technology in the US." Tyler's expertise aligns closely with ProVerum's mission to innovate and enhance care solutions for BPH, which affects millions of men worldwide.
The current Chairman of ProVerum's Board, Dave Amerson, added, "Having worked with Tyler for many years, I have firsthand knowledge of his ability to help drive rapid growth. His appointment brings significant value to ProVerum." This statement harmonizes with the collective confidence in Tyler's ability to steer the company through the complexities of the medical technology landscape.
ProVerum Ltd., headquartered in Dublin, is committed to revolutionizing how BPH is treated, and as such, the ProVee® System remains central to this vision. However, it is important to note that this investigational device is currently limited to investigational use and is not available for sale in the United States due to federal regulations.
For more details on ProVerum Ltd. and the ProVee® System, you can visit their official website at www.proverummedical.com. The company is keen on connectivity and collaboration through platforms like X and LinkedIn, which allows stakeholders and interested parties to stay updated on their advancements and commercialization efforts. As ProVerum continues its trajectory towards launching this groundbreaking device, Binney's strategic leadership and innovative mindset will undoubtedly play a pivotal role in its future successes in the BPH treatment market.
With an impressive background in the medical device industry, Tyler Binney has previously held notable positions, which include President and CEO of Relievant Medsystems, Inc. His tenure there ended with a successful acquisition by Boston Scientific in November 2023, a deal that underscored Tyler's capability in driving commercial success, considering it was valued at $850 million along with performance-based earnouts. Furthermore, his earlier experience encompasses leadership roles at Teleflex and NeoTract, where he excelled in promoting innovative urology technologies.
In expressing his enthusiasm for joining ProVerum, Binney stated, "I am thrilled to join the ProVerum Board at such an exciting time in the company's growth. The ProVee® System truly has the potential to transform the way BPH is managed and treated. I look forward to contributing to that success and supporting ProVerum's executive management as they prepare for commercialization." This sentiment highlights not only his optimism but also the transformative potential of the ProVee® System within the healthcare landscape.
Paul Bateman, CEO of ProVerum, welcomed Binney's addition to the team, stating, "Tyler brings a wealth of experience in launching disruptive technologies and developing high-growth companies. His knowledge of the BPH market will be invaluable as we work to launch our novel technology in the US." Tyler's expertise aligns closely with ProVerum's mission to innovate and enhance care solutions for BPH, which affects millions of men worldwide.
The current Chairman of ProVerum's Board, Dave Amerson, added, "Having worked with Tyler for many years, I have firsthand knowledge of his ability to help drive rapid growth. His appointment brings significant value to ProVerum." This statement harmonizes with the collective confidence in Tyler's ability to steer the company through the complexities of the medical technology landscape.
ProVerum Ltd., headquartered in Dublin, is committed to revolutionizing how BPH is treated, and as such, the ProVee® System remains central to this vision. However, it is important to note that this investigational device is currently limited to investigational use and is not available for sale in the United States due to federal regulations.
For more details on ProVerum Ltd. and the ProVee® System, you can visit their official website at www.proverummedical.com. The company is keen on connectivity and collaboration through platforms like X and LinkedIn, which allows stakeholders and interested parties to stay updated on their advancements and commercialization efforts. As ProVerum continues its trajectory towards launching this groundbreaking device, Binney's strategic leadership and innovative mindset will undoubtedly play a pivotal role in its future successes in the BPH treatment market.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.